Back to All Combinations

Right-Sided Primary

Poor Prognosis
40.00% Prevalence Level 1 Tumor Location
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
Location
Treatment Implications

Higher BRAF, MSI-H. Worse prognosis. Check MSI always.

Recommended Treatments
Intensive chemotherapy
Bevacizumab-based
Treatments to Avoid

No specific contraindications noted

Study References

CALGB 80405

Key Statistics
40.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Different biology regardless of RAS status.
Information

Category: Tumor Location

Evidence Level: Level 1

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.